AQR Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-91,733
| Closed | -$1.85M | – | 2327 |
|
|
2021
Q3 | $1.85M | Buy |
91,733
+52,741
| +135% | +$1.46M | ﹤0.01% | 1194 |
|
|
2021
Q2 | $1.46M | Sell |
38,992
-28,881
| -43% | -$885K | ﹤0.01% | 1403 |
|
|
2021
Q1 | $1.74M | Buy |
67,873
+9,567
| +16% | +$244K | ﹤0.01% | 1279 |
|
|
2020
Q4 | $1.28M | Sell |
58,306
-52,060
| -47% | -$1.15M | ﹤0.01% | 1389 |
|
|
2020
Q3 | $1.99M | Sell |
110,366
-20,577
| -16% | -$426K | ﹤0.01% | 1110 |
|
|
2020
Q2 | $3.33M | Buy |
130,943
+3,612
| +3% | +$77.8K | 0.01% | 937 |
|
|
2020
Q1 | $2.34M | Buy |
127,331
+107,252
| +534% | +$2.08M | ﹤0.01% | 1022 |
|
|
2019
Q4 | $442K | Buy |
20,079
+2,372
| +13% | +$47.7K | ﹤0.01% | 1790 |
|
|
2019
Q3 | $254K | Sell |
17,707
-21,936
| -55% | -$314K | ﹤0.01% | 1956 |
|
|
2019
Q2 | $624K | Buy |
39,643
+3,919
| +11% | +$53.3K | ﹤0.01% | 1659 |
|
|
2019
Q1 | $523K | Sell |
35,724
-14,557
| -29% | -$167K | ﹤0.01% | 1787 |
|
|
2018
Q4 | $538K | Buy |
50,281
+6,120
| +14% | +$80.5K | ﹤0.01% | 1747 |
|
|
2018
Q3 | $674K | Buy |
44,161
+983
| +2% | +$14.3K | ﹤0.01% | 1849 |
|
|
2018
Q2 | $529K | Buy |
+43,178
| New | +$542K | ﹤0.01% | 1963 |
|
|
2016
Q2 | – | Sell |
-41,758
| Closed | -$224K | – | 2286 |
|
|
2016
Q1 | $224K | Sell |
41,758
-50,682
| -55% | -$320K | ﹤0.01% | 2084 |
|
|
2015
Q4 | $1.1M | Buy |
92,440
+15,762
| +21% | +$180K | ﹤0.01% | 1525 |
|
|
2015
Q3 | $630K | Buy |
76,678
+32,219
| +72% | +$372K | ﹤0.01% | 1636 |
|
|
2015
Q2 | $620K | Buy |
+44,459
| New | +$815K | ﹤0.01% | 1697 |
|
Other funds holding DRNA
AQR Capital Management's DRNA Position: Q4 2021 in Review
AQR Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 91,733 shares — an estimated $1.85M sold.
AQR Capital Management first reported a position in DRNA in Q2 2015 and held it in 18 quarters. The position peaked at $3.33M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- AQR Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- AQR Capital Management sold 91,733 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.85M.
- AQR Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2015 and held it in 18 quarters.
- AQR Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $3.33M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on AQR Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.